Compare ARCO & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCO | AMLX |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | Uruguay | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2011 | 2021 |
| Metric | ARCO | AMLX |
|---|---|---|
| Price | $9.59 | $17.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $8.60 | ★ $20.11 |
| AVG Volume (30 Days) | 801.2K | ★ 1.2M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | $12.56 | N/A |
| Revenue Next Year | $3.48 | N/A |
| P/E Ratio | $7.26 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $6.51 | $4.41 |
| 52 Week High | $9.03 | $18.61 |
| Indicator | ARCO | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 75.02 | 64.35 |
| Support Level | $7.04 | $13.19 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.24 | 0.91 |
| MACD | 0.11 | 0.26 |
| Stochastic Oscillator | 89.80 | 83.26 |
Arcos Dorados Holdings Inc operates McDonald's branded restaurants in various countries and territories in Latin America and the Caribbean. The Company manages its business as distinct geographic segments and its operations are divided into three geographic divisions, as follows: Brazil, the North Latin American division, or NOLAD, which is comprised of Costa Rica, Mexico, Panama, Puerto Rico, Martinique, Guadeloupe, French Guiana and the U.S. Virgin Islands of St. Croix and St. Thomas and the South Latin American division, or SLAD, which is comprised of Argentina, Chile, Ecuador, Peru, Uruguay, Colombia, Venezuela, Trinidad and Tobago, Aruba and Curacao. Their menu includes hamburgers, McNuggets, salad, sandwiches, French fries, and others.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.